{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:02:43Z","timestamp":1792180963938,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01535-6","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:33:19Z","timestamp":1784539999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["First-Line Immunotherapy Versus Chemotherapy in MSI-H\/dMMR Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis of Phase III Studies"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4956-9551","authenticated-orcid":false,"given":"Wala","family":"Ben Kridis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afef","family":"Khanfir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"23","key":"1535_CR1","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2017699","journal-title":"N Engl J Med"},{"issue":"21","key":"1535_CR2","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","volume":"391","author":"T Andre","year":"2024","unstructured":"Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, et al. Nivolumab plus Ipilimumab in microsatellite-instability-high metastatic colorectal cancer. N Engl J Med. 2024;391(21):2014\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2402141","journal-title":"N Engl J Med"},{"issue":"8","key":"1535_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"T Andr\u00e9","year":"2018","unstructured":"Andr\u00e9 T, Kopetz S, Kamble S, Cao A, Ledeine J-M, et al. Durable clinical benefit with nivolumab plus ipilimumab in dna mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773\u20139. . https:\/\/doi.org\/10.1200\/JCO.2017.76.9901","journal-title":"J Clin Oncol"},{"issue":"17","key":"1535_CR4","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.3390\/cancers15174245","volume":"15","author":"J Ros","year":"2023","unstructured":"Ros J, Baraibar I, Saoudi N, Rodriguez M, Salv\u00e0 F, Tabernero J, et al. Immunotherapy for colorectal cancer with high microsatellite instability: the ongoing search for biomarkers. Cancers (Basel). 2023;15(17):4245. https:\/\/doi.org\/10.3390\/cancers15174245","journal-title":"Cancers (Basel)"},{"key":"1535_CR5","doi-asserted-by":"publisher","first-page":"1032314","DOI":"10.3389\/fimmu.2022.1032314","volume":"13","author":"W Hou","year":"2022","unstructured":"Hou W, Yi C, Zhu H. Predictive biomarkers of colon cancer immunotherapy: present and future. Front Immunol. 2022;13:1032314. https:\/\/doi.org\/10.3389\/fimmu.2022.1032314","journal-title":"Front Immunol"},{"issue":"2","key":"1535_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1177\/0962280214557578","volume":"26","author":"NR Latimer","year":"2014","unstructured":"Latimer NR, Abrams K, Lambert P, et al. Adjusting for treatment switching in randomised controlled trials \u2013 A simulation study and a simplified two-stage method. Stat Methods Med Res. 2014;26(2):724\u201351. https:\/\/doi.org\/10.1177\/0962280214557578.","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"1535_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/0272989X13520192","volume":"34","author":"NR Latimer","year":"2014","unstructured":"Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, et al. Adjusting survival time estimates to account for treatment switching in randomized controlled trials\u2013an economic evaluation context: methods, limitations, and recommendations. Med Decis Mak. 2014;34(3):387\u2013402.","journal-title":"Med Decis Mak"},{"issue":"8","key":"1535_CR8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1056\/NEJMc2409154","volume":"392","author":"B Rousseau","year":"2025","unstructured":"Rousseau B, White JR, Cercek A, Diaz LA Jr. The duration of immunotherapy for mismatch repair-deficient cancers. N Engl J Med. 2025;392(8):824\u20136. https:\/\/doi.org\/10.1056\/NEJMc2409154","journal-title":"N Engl J Med"},{"issue":"6349","key":"1535_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313. https:\/\/doi.org\/10.1126\/science.aan6733","journal-title":"Science"},{"issue":"11","key":"1535_CR10","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/nm.4191","volume":"22","author":"RJ Hause","year":"2016","unstructured":"Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11):1342\u201350. https:\/\/doi.org\/10.1038\/nm.4191","journal-title":"Nat Med"},{"issue":"6230","key":"1535_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138. https:\/\/doi.org\/10.1126\/science.aaa1348","journal-title":"Science"},{"issue":"1","key":"1535_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","volume":"5","author":"NJ Llosa","year":"2015","unstructured":"Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0863","journal-title":"Cancer Discov"},{"issue":"6377","key":"1535_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.aan5951","volume":"359","author":"D Miao","year":"2018","unstructured":"Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801\u20136. https:\/\/doi.org\/10.1126\/science.aan5951","journal-title":"Science"},{"issue":"6411","key":"1535_CR14","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411):eaar3593. . https:\/\/doi.org\/10.1126\/science.aar3593","journal-title":"Science"},{"key":"1535_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"issue":"12","key":"1535_CR16","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338.","journal-title":"Ann Oncol"},{"issue":"12","key":"1535_CR17","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40265-025-02243-4","volume":"85","author":"PE Abraham","year":"2025","unstructured":"Abraham PE, Johnson DB. Long-term toxicities of immune checkpoint inhibitors. Drugs. 2025;85(12):1535\u201349. https:\/\/doi.org\/10.1007\/s40265-025-02243-4","journal-title":"Drugs"},{"issue":"7414","key":"1535_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01535-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01535-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01535-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:33:19Z","timestamp":1784539999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01535-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1535"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01535-6","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"159"}}